Enanta Pharmaceuticals Inc.
ENTA | NASDAQ
$12.25
+$0.14 (+1.16%)
Sep 22, 2026, 11:21 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Sep 29, 2025 | FY 2024 Sep 29, 2024 | FY 2023 Sep 29, 2023 | FY 2022 Sep 29, 2022 | FY 2021 Sep 29, 2021 | FY 2020 Sep 29, 2020 |
|---|---|---|---|---|---|---|
Revenue | 65.32M | 67.64M | 79.2M | 86.16M | 97.07M | 122.47M |
Cost of Revenue | 4.59M | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 60.74M | 67.64M | 79.2M | 86.16M | 97.07M | 122.47M |
Operating Income | -85.35M | -121.69M | -137.21M | -123.84M | -109.57M | -41.64M |
Interest Income | 9.48M | 14.77M | 11.36M | 1.57M | 2.02M | 6.47M |
Pretax Income | -83.55M | -117.79M | -131M | -122.19M | -107.58M | -35.02M |
Net Income | -81.89M | -116.05M | -133.82M | -121.76M | -79M | -36.17M |
Selling & General & Admin | 43.93M | 57.85M | 52.89M | 45.48M | 32.54M | 27.36M |
Research & Development | 106.74M | 131.48M | 163.52M | 164.52M | 174.11M | 136.76M |
Other Expenses | -4.59M | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 146.09M | 189.33M | 216.41M | 210M | 206.65M | 164.11M |
Interest Expense | 7.68M | 10.94M | 5.15M | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 150.67M | 189.33M | 216.41M | 210M | 206.65M | 164.11M |
Income Tax Expense | -1.66M | -1.74M | 2.82M | -433K | -28.58M | 1.15M |
Shares Outstanding (Basic) | 21.34M | 21.16M | 20.97M | 20.6M | 20.17M | 19.94M |
Shares Outstanding (Diluted) | 21.34M | 21.16M | 20.97M | 20.6M | 20.17M | 19.94M |
EPS (Basic) | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 |
EPS (Diluted) | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 |
EBITDA | -70.78M | -104.51M | -123.48M | -119.22M | -104.25M | -38M |
EBIT | -75.87M | -106.85M | -125.85M | -122.19M | -107.58M | -41.64M |
Depreciation & Amortization | 5.09M | 2.34M | 2.37M | 2.97M | 3.33M | 3.64M |
Add to Watchlist
Select watchlists to add or remove ENTA